Cellular Signaling in Cancer

Dear Colleagues,

Cancer is the second leading cause of death after cardiovascular disease, and despite the enormous efforts in advancing anti-cancer agents, it is still challenging to treat cancer. This multifaceted disease is characterized by six hallmarks: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. This Special Issue focuses on key signaling pathways involved in tumorigenesis, progression, and drug resistance. Several signaling pathways have been identified as frequently altered in cancer that led to uncontrolled cell proliferation, survival, and invasion, driving the disease's progression. Identifying the critical cellular signaling in cancer vs. normal cells can lead to the development of targeted therapy aimed at specific signaling molecules. Targeted therapy, whether used alone or in combination with other conventional treatments such as chemotherapy, radiotherapy, or surgery, can lead to more effective cancer therapies while minimizing the harmful effects on healthy cells. Advancements in various cancer types have arisen, with targeted approaches significantly improving patient outcomes. Continued research into cell signaling mechanisms holds promise for identifying novel therapeutic targets and improving cancer treatment strategies. As we deepen our understanding of the complexity and interactions within signaling pathways, personalized medicine may become a more standard form of cancer care, allowing for tailored treatments based on the unique molecular profiles of individual tumors.

Dr. Avisek Majumder
Guest Editor

Dr. Shabana Bano
Dr. Kasturi Nayak
Guest Editor Assistants

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.